- Correction
- Open access
- Published:
Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
Arthritis Research & Therapy volume 25, Article number: 24 (2023)
The Original Article was published on 27 October 2022
Correction: Arthritis Res Ther 24, 240 (2022)
https://doi.org/10.1186/s13075-022-02934-3
Following publication of the original article [1], the authors reported an error in Additional file 1: Figure S1, Panel (C), subpanel c) a description regarding the gating strategy for the activated Th17 cells.
The data currently reads:
-
Activated Th17 cells: CD3+, CD4+, CXCR3+, CCR6+, CD38+, HLA-DR+
The data should read:
-
Activated Th17 cells: CD3+, CD4+, CXCR3-, CCR6+, CD38+, HLA-DR+
Reference
Ueno M, Miyagawa I, Miyazaki Y, et al. Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis Res Ther. 2022;24:240. https://doi.org/10.1186/s13075-022-02934-3.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Additional file 1: Figure S1.
Flow cytometry gating strategy. The proportion of A. CD4+ T cells subsets to CD3+ and CD4+ T cells (%), B. CD8+ T cells subsets to CD3+ and CD8+ T cells (%), C. a)-e) Activated CD4+ T cells to CD3+ and CD4+ T cells (%) f) Activated CD8+ T cells to CD3+ and CD8+ T cells (%), D. B cells subsets to CD3- and CD19+ B cells (%), E. Classical and non-classical monocytes to CD3-, CD19-, CD20- and CD14+ cells (%), F. Myeloid and Plasmacytoid DCs to CD3-, CD19-, CD20- CD14- and human leukocyte antigen-DR+ cells (%), G. CD16+ and CD16- NK cells to CD3-, CD19-, CD20- CD14- and CD56+ cells (%).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ueno, M., Miyagawa, I., Miyazaki, Y. et al. Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes. Arthritis Res Ther 25, 24 (2023). https://doi.org/10.1186/s13075-023-03005-x
Published:
DOI: https://doi.org/10.1186/s13075-023-03005-x